Company intelligence / Profile preview

Restore Vision Inc.

Ownership: Private
Development stage: Preclinical

Overview

The company announced dosing of the first patient in a Phase I/II clinical trial of RV‑001 for gene‑agnostic retinitis pigmentosa in February 2025. No published efficacy results yet; the program aims to address inherited retinal disease regardless of genetic mutation[1].

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (specifically visual restoration gene therapy)
Industry: Biotech

Drug pipeline

1 asset

RV-001

Unknown

Beyond the preview

Go deeper on Restore Vision Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Restore Vision Inc..

Explore the full profile